REPLIMUNE GROUP, INC. Repayments of Long-Term Debt
REPLIMUNE GROUP, INC. (REPL) reported Repayments of Long-Term Debt of $0 for the 12-month period ending 2022-03-31, per its 10-K filed 2022-05-19.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2022-05-19
- REPLIMUNE GROUP, INC. repayments of long-term debt for the quarter ending 2022-03-31 was $0.00.
- REPLIMUNE GROUP, INC. repayments of long-term debt for the quarter ending 2021-03-31 was $0.00.
- REPLIMUNE GROUP, INC. repayments of long-term debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- REPLIMUNE GROUP, INC. repayments of long-term debt for fiscal 2021 was $10.00M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19 | $0.00 10-K · filed 2022-05-19 | |
| 2021-12-31 | $0.00 10-Q · filed 2022-02-03 | ||
| 2021-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19 | $10.00M 10-K · filed 2022-05-19 | |
| 2020-12-31 | $10.00M 10-Q · filed 2022-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |